Nuvaira - About the company
Nuvaira is a series E company based in Minneapolis (United States), founded in 2008 by Martin Mayse. It operates as a Provider of a catheter-based system for patients suffering from COPD. Nuvaira has raised $227M in funding from investors like USVP, Advanced Technology Ventures and Endeavour Vision. The company has 3 active competitors, including 1 funded and 1 that has exited. Its top competitors are Asthmatx and D R Burton.
Company Details
Provider of a catheter-based system for patients suffering from COPD. The company is developing Nuvaira Lung Denervation System, a catheter-based system used to treat the overactive airway nerves in a procedure called Targeted Lung Denervation (TLD). It provides an ablative therapy that opens obstructed airways to improve breathing.
- Website
- nuvaira.com
- Social
- Email ID
- *****@nuvaira.com
- Phone Number
- +1 **********
Key Metrics
Founded Year
2008
Location
Minneapolis, United States
Stage
Series E
Total Funding
$227M in 10 rounds
Latest Funding Round
Ranked
1st among 3 active competitors
Employee Count
20 as on Sep 30, 2026
Legal entities associated with Nuvaira
Nuvaira is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
Nuvaira, Inc. CIN: 263112330 , United States, Active | Dec 31, 1999 | - | 18 (As on Dec 31, 2024) | - |
Sign up to download Nuvaira's company profile
Nuvaira's funding and investors
Nuvaira has raised a total funding of $227M over 10 rounds. Its first funding round was on Apr 14, 2009. Nuvaira has 14 institutional investors.
Here is the list of recent funding rounds of Nuvaira:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Feb 20, 2026 | 8132605 | Series E | 9322733 | 3727933 | 6019247 | 8342261 |
Nov 28, 2023 | 9063016 | Series E | 9884480 | 6229112 | 4756091 | 4185047 |
Jan 19, 2022 | 2773709 | Series E | 3295466 | 7449423 | 1079238 | 7727304 |
Access funding benchmarks and valuations. Sign up today!View details of Nuvaira's funding rounds and investors
Nuvaira's founders and board of directors
Founder? Claim ProfileThe founders of Nuvaira is Martin Mayse.
Here are the details of Nuvaira's key team members:
- Martin Mayse: Former Co-Founder of Nuvaira and founder of 1 other company. Contact Info: 1 email address
View details of Nuvaira's Founder profiles and Board Members
Nuvaira's employee count trend
Nuvaira has 20 employees as of Sep 26. Here is Nuvaira's employee count trend over the years:
Uncover Nuvaira's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Nuvaira's Competitors and alternates
Top competitors of Nuvaira include Asthmatx and D R Burton. Here is the list of Top 10 competitors of Nuvaira, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Nuvaira 2008, Minneapolis (United States), Series E | Provider of a catheter-based system for patients suffering from COPD | $227M | 60/100 | |
2nd | Asthmatx 2003, Sunnyvale (United States), Acquired | SEO, web hosting, lighting, and hardware solutions for home and business | $50M | 39/100 | |
3rd |  D R Burton 2015, Raleigh (United States), Unfunded | Provider of products for generating positive pressure for lung disease patients | - | - | 29/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Nuvaira's competitors? Click here to see the top ones
Nuvaira's Investments and acquisitions
Nuvaira has made no investments or acquisitions yet.
Reports related to Nuvaira
Here is the latest report on Nuvaira's sector:
News related to Nuvaira
Filter this listMedia has covered Nuvaira for 1 event in last 1 year.
•
•
•
Nuvaira Announces Published Two-Year Results in COPD Patients treated with Targeted Lung DenervationPR Newswire•Nov 23, 2020•Nuvaira
•
Nuvaira® Lung Denervation System Designated as a Breakthrough Device by the FDAMedical Device News•Jun 08, 2020•Nuvaira
•
Nuvaira Announces Chief Financial Officer and Pivotal Study MilestonePR Newswire•Feb 04, 2020•Nuvaira, Avedro
•
Nuvaira Announces Peer-Reviewed Publications of Targeted Lung Denervation Mechanisms of Action and Clinical OutcomesPR Newswire•Aug 19, 2019•Nuvaira
•
First patients successfully treated in the Nuvaira AIRFLOW-3 COPD pivotal trialPR Newswire•Jun 10, 2019•Nuvaira
•
First patients successfully treated in the Nuvaira AIRFLOW-3 COPD pivotal trialPR Newswire•Jun 10, 2019•Nuvaira
•
Nuvaira Receives French Innovation Funding for AIRFLOW-3 Pivotal TrialPR Newswire•May 02, 2019•Nuvaira
•
Nuvaira Announces a $79 Million Financing Round to Pursue Groundbreaking Treatment of COPDPR Newswire•Feb 11, 2019•Nuvaira
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Nuvaira
Explore our recently published companies
- Everlyrings - Johns Island based, Unfunded company
- Shenzhen Lanmage Medical Technology - Shenzhen based, 2015 founded, Unfunded company
- Orraj - 2016 founded, Unfunded company
- Cpapequipsource - Unfunded company
- ZondaLabs - Switzerland based, Unfunded company
- Asntech - Germany based, Unfunded company
